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OBJECTIVE—Diabetes results from a deﬁciency of functional
-cells due to both an increase in -cell death and an inhibition
of -cell replication. The molecular mechanisms responsible for
these effects in susceptible individuals are mostly unknown. The
objective of this study was to determine whether a gene critical
for cell division and cell survival in cancer cells, survivin, might
also be important for -cells.
RESEARCH DESIGN AND METHODS—We generated mice
harboring a conditional deletion of survivin in pancreatic endo-
crine cells using mice with a Pax-6-Cre transgene promoter
construct driving tissue-speciﬁc expression of Cre-recombinase
in these cells. We performed metabolic studies and immuno-
histochemical analyses to determine the effects of a mono- and
biallelic deletion of survivin.
RESULTS—Selective deletion of survivin in pancreatic endo-
crine cells in the mouse had no discernible effects during
embryogenesis but was associated with striking decreases in
-cell number after birth, leading to hyperglycemia and early-
onset diabetes by 4 weeks of age. Serum insulin levels were
signiﬁcantly decreased in animals lacking endocrine cell sur-
vivin, with relative stability of other hormones. Exogenous
expression of survivin in mature -cells lacking endogenous
survivin completely rescued the hyperglycemic phenotype and
the decrease in -cell mass, conﬁrming the speciﬁcity of the
survivin effect in these cells.
CONCLUSIONS—Our ﬁndings implicate survivin in the main-
tenance of -cell mass through both replication and anti-
apoptotic mechanisms. Given the widespread involvement of
survivin in cancer, a novel role for survivin may well be exploited
in -cell regulation in diseased states, such as diabetes.
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P
roduction and maintenance of the pancreatic
-cell mass is a highly regulated process driven
by mechanisms that differ in developing com-
pared with adult animals. These mechanisms
include, but are not limited to, -cell replication, -cell
hypertrophy, -cell differentiation (neogenesis), and -cell
apoptosis (1–3), each having variable importance depend-
ing on the age of the animal and changes in the metabolic
demands of the body. During early embryogenesis in the
mouse, most -cells are generated through endocrine cell
differentiation, a process that depends on key transcrip-
tion factors, including Pdx1, Isl1, Nkx2.2, Nkx6.1, and the
Maf proteins (4,5). Differentiated -cells ﬁrst appear
around embryonic day (E) 13 at the start of a wave of the
secondary transition. During late embryogenesis (E18.5)
and immediately after birth, a transient burst of replication
of these -cells occurs (1,6,7) with a consequent marked
increase in -cell growth (2,8). New -cells continue to
form in the adult animal, primarily from the replication of
mature -cells (9,10). The mechanism by which fully
differentiated, mature -cells can reenter the cell cycle
without undergoing a process of programmed cell death is
unclear.
An attractive candidate regulator of -cell replication
and survival after birth is survivin, a cancer gene impli-
cated in both the control of cell division and the regulation
of apoptosis in cancer cells but with unknown functions in
most normal cells (11–13). Survivin was originally discov-
ered as a homolog to the inhibitor of apoptosis proteins in
cancer cells (14). These proteins block the function of
caspase proteins in the mitochondria-dependent cell death
pathway (15), protecting cells from succumbing to a
cascade of cellular and molecular events that characterize
apoptosis. Survivin is a potent inhibitor of cell death in
diverse malignant tumor cell types (11) and in some
normal cells, including hepatocytes (16) and bone marrow
stem cells (17). In addition, survivin also plays a role in cell
division in some normal cells during embryogenesis and in
cancer cells. Biallelic deletion of survivin in embryonic
stem cells leads to embryonic lethality between E4 and E6
(18), with cells lacking survivin having abnormal, enlarged
nuclei. This phenotype parallels that of other genetic
models targeting proteins known as chromosomal passen-
ger proteins (CPPs) (19). Survivin forms a complex with
other CPPs and plays an active role in recruiting aurora
kinase B to the kinetochore to ensure the proper regula-
tion of cytokinesis (20). A clear understanding of how
survivin regulates both cell division and apoptosis is not
known. Some evidence suggests that the protein exists in
multiple subcellular pools (21) and can interact with
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forms (25), to perform these different functions.
Survivin is expressed in a range of normal embryonic
tissues and in a restricted number of highly proliferative
adult tissues (26), including bone marrow–derived stem
cells (17) and neural progenitor cells (27). Its expression
during both normal development and cancer suggests that
it is a critical molecule for maintaining cellular homeosta-
sis and that its aberrant regulation can contribute to either
disease initiation or progression. Recently, exogenous
expression of survivin in a streptozotocin-induced model
of diabetes demonstrated protection of pancreatic -cells
from programmed cell death (28). This provides some
evidence that it may play a role as an apoptotic inhibitor in
-cells in the setting of diabetes. Based on the bifunctional
role of survivin in cancer and in stem cells, we hypothe-
sized that it may play a role in the replication and/or
survival of mature pancreatic -cells after birth.
RESEARCH DESIGN AND METHODS
Pax6-Cre mice (also called Le-Cre) were crossed with B6;129S-Gtrosa26
tm1sor
mice to evaluate Cre activity (29). Mice harboring a conditionally targeted
mouse survivin gene ﬂanked by two loxP sites (survivin
lox/lox) have been
described previously (16,27), as have Pax6-Cre mice (30). Pax6-Cre mice
were crossed with survivin
lox/lox mice to generate Pax6-Cre;survivin
lox/lox
mice. For the rescue experiment, two lines of mice harboring a mouse
survivin transgene under control of an rat insulin promoter (RIP) (28) were
mated with survivin
lox/lox mice. Offspring with the genotype of Pax6-Cre;RIP-
SVV
; survivin
lox/lox were compared with those of with Pax6-Cre; RIP-SVV
;
survivin
lox/lox mice. All experimental procedures were performed with the
approval of the Institutional Animal Care and Use Committee. Islet isolation
was as previously described (31).
Morphometry and islet mass. Serial pancreatic sections were collected
every 100 m and stained with hematoxylin-eosin (H-E). Images were taken
with a Leica microscope equipped with a SPOT RT KE digital camera
(Diagnostic Instruments). Islet cell areas for the control and survivin knock-
out were measured by point counting morphometry (see the supplemental
methods available in an online appendix at http://dx.doi.org/10.2337/db08-
0170).
Immunohistochemistry. Pancreata were ﬁxed in either 10% neutral-buffered
formalin or Histochoice (Ameresco), dehydrated through a graded series of
ethanol, and embedded in parafﬁn wax. Sections were cut and stained with
H-E. For ﬂuorescent immunostaining, fresh frozen sections were cut and ﬁxed
in 4% paraformaldehyde. The primary antibodies used were survivin (TIAP;
rabbit polyclonal, 1:200; Chemicon), glucagon (mouse monoclonal, 1:1,000;
Sigma), somatostatin (rabbit polyclonal anti-srif28 IHC 8004, 1:1,000; Penin-
sula), active caspase 3 (rabbit, 1:20; Abcam), insulin (guinea pig, 1:200; Linco),
MafB (rabbit, 1:100; Bethyl Laboratories), Nkx2.2 (mouse, 1:100; Developmen-
tal Studies Hybridoma Bank), mouse Nkx6.1 (rabbit, 1:500; provided by Dr. P.
Serup), Pax6 (rabbit, 1:500; Covance), -catenin (mouse, 1:100; BD Bio-
sciences), and Isl1 (mouse, 1:100; Developmental Studies Hybridoma Bank).
Rabbit anti-MafA antibody was described previously (32). Apoptosis was
assayed with the FragELTM kit (Calbiochem), according to the manufactur-
er’s instructions.
Metabolic studies. Serum blood glucoses were measured with One Touch
InDuo Glucometer and test strips (Lifescan, Milpitas, CA). For the glucose
challenge, mice were fasted then injected intraperitoneally with dextrose at 2
g/kg body wt. Blood glucose levels were subsequently measured at indicated
times. Insulin challenge was performed in the fed state. A dose of 0.75 unit/kg
body wt was injected intraperitoneally. Blood glucose levels were measured
every 15 min for 90 min after injection. A minimum of four animals per group
per time point was used for each of these measurements.
RESULTS
Survivin is dispensable for endocrine cell differenti-
ation during embryogenesis. To gain insight into the
regulatory potential of survivin in pancreatic -cells, we
determined its expression pattern in the mouse pancreas
during normal embryonic development and after birth.
Survivin protein was readily detected throughout the
pancreatic epithelium, including endocrine cells during
the secondary transition (E15.5), as shown by the cyto-
plasmic staining of survivin in cells that express -catenin,
insulin, and Isl1 (Fig. 1A). Survivin expression gradually
became restricted to endocrine (Isl1
) cells in late embry-
ogenesis (E19.5) and postnatally (postnatal day [P] 14)
(Fig. 1A). By P21, one can detect several Isl1
 cells that do
not express survivin, suggesting a further restriction of
survivin expression to a subpopulation(s) of endocrine
cells (Fig. 1A). Colocalization of survivin with insulin was
also observed at these time points, with a relative lack of
survivin staining within cells that stained positive for
glucagon and somatostatin (Fig. 1A, panel 2), suggesting
that survivin expression becomes restricted to -cells by
P21. Expression of survivin in mature, differentiated
-cells after birth was unexpected, because activation of
this gene was previously reported only in undifferentiated
and highly proliferating cells in the adult animal (26).
Therefore, we conﬁrmed the expression of survivin in
these cells by isolating islets from normal mice at 1 and 2
weeks after birth and performing RT-PCR for survivin,
insulin, and glyceraldehyde-3-phosphate dehydrogenase
(supplementary Fig. 1A. The pattern of survivin expression
within the pancreas is similar to the reported pattern of
key transcription factors that contribute to -cell develop-
ment during embryogenesis and after birth, including
Nkx6.1 and Pdx1 (5,33). It is possible that such factors
may restrict survivin expression to -cells during the
postnatal period.
To examine the functional role of survivin in all pancre-
atic endocrine cells both during embryogenesis and after
birth, we chose a Pax6-Cre transgene construct (also
known as Le-Cre) that drives tissue-speciﬁc expression of
Cre-recombinase in the cells expressing Pax6 (30). The
onset of endogenous Pax6 expression normally occurs at
E9.5 in mouse endocrine progenitors and persists in
mature endocrine cells throughout development and post-
natally, thus providing us with a tool to examine the role of
survivin in all endocrine cells during fetal development
and postnatally (30,34). The construct incorporated a
6.5-kb genomic region of the mouse Pax6 promoter that
has been previously shown to initiate transcription of
Pax6 in the lens and in developing pancreatic endocrine
cells but not in other pancreatic cells or in the central
nervous system (34). We further characterized the expres-
sion pattern of Cre-recombinase within the pancreas of
Pax6-Cre mice after birth by mating them with Rosa26
Cre-reporter mice [Gt(ROSA)26Sor
tm1Sor], collecting pan-
creatic tissues, and staining sections with X-Gal. -Galac-
tosidase was expressed in all endocrine-producing cells
but not in exocrine cells, conﬁrming the speciﬁcity of the
Pax6 promoter within the pancreas after birth (supple-
mentary Fig. 1B).
To determine the potential effects of survivin on endo-
crine cell differentiation during embryogenesis and its
effects on cell survival after birth, Pax6-Cre mice were
bred to mice carrying the mouse survivin gene ﬂanked by
two loxP sites, generating Pax6-Cre;survivin
lox/lox mice,
deleting survivin in Pax6-expressing cells. Deletion of
survivin within the pancreatic endocrine cells of affected
mice was conﬁrmed both by staining pancreas tissue from
control and mutant animals with an antibody to survivin
(Fig. 1B, panel 1) and by performing PCR for the deleted
and nondeleted survivin alleles on isolated islet cell DNA
(supplementary Fig. 1C). Quantiﬁcation of survivin and
insulin protein in the knockout animals showed that only
6% of all insulin
 cells expressed survivin. By compari-
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pressed survivin; therefore, we estimated a 94%
efﬁciency of recombination in this model. To demonstrate
the speciﬁcity of the survivin deletion to pancreatic
endocrine tissue of Pax6-Cre;survivin
lox/lox animals, we
performed PCR for the deleted and nondeleted survivin
alleles in tissues outside the pancreas, including liver,
muscle, fat, and brain (supplementary Fig. 1D), and
showed that the survivin gene was largely intact in these
other tissues. A minor amount of a second product was
detected in fat that may represent the deleted allele. This
could indicate that there is some recombination in fat;
however, no prior evidence of Pax6 expression in adipose
tissue has been reported.
Examination of the expression pattern of key proteins
in endocrine cell differentiation during embryogenesis
showed that mice lacking endocrine-survivin had essen-
tially the same expression pattern of these factors (Pdx1,
Isl1, Nkx2.2, and the Maf proteins) in endocrine precur-
sors as did their littermate controls (Fig. 1B, panels 2 and
3). Based on these data, survivin may be dispensable for
the proliferation of pancreatic progenitors and the differ-
entiation of pancreatic endocrine cells during embryogen-
esis. The lack of identiﬁable effects on cell number during
this time period was somewhat surprising because con-
ventional deletion of survivin in embryonic stem cells
resulted in early embryonic lethality (18) and because
deletion of survivin at E9.5 in neural stem cells led to
signiﬁcant embryonic neural stem cell loss and death
immediately after birth (27). By contrast, here, all Pax6-
Cre;survivin
lox/lox mice were born in the expected Mende-
lian ratios, suggesting no embryonic lethality, and had
birth weights and sizes similar to those of littermate
controls (not shown), suggesting no signiﬁcant metabolic
effects in utero.
Survivin is required for mature -cell function after
birth. To determine the potential physiological effects of
survivin loss within the endocrine cells after birth, we
performed serial metabolic studies on mice lacking endo-
crine-survivin (Pax6-Cre;survivin
lox/lox mice). During the
ﬁrst 3 weeks after birth, survivin-deﬁcient animals had
random glucose levels that were similar to their littermate
controls with intact survivin genes (Fig. 2A). At 4 weeks
of life, however, the Pax6-Cre;survivin
lox/lox mice devel-
oped hyperglycemia (Fig. 2A) and a reduced glucose
tolerance, as determined by injection with 2 g/kg dextrose
after a 5-h fast (Fig. 2B), ﬁndings consistent with early-
onset diabetes. The glucose abnormalities in these mice
E15.5
P7 P21
E19.5 P14 P21
Survivin/β-Catenin
Survivin/Isl1
Survivin/Ins
Survivin/Gluc
Survivin/Som
A
FIG. 1. Survivin expression becomes gradually re-
stricted to -cells after birth. A: Survivin expression in
pancreatic endocrine and exocrine cells from E15.5 to
P21, assessed by immunoﬂuorescent staining of pan-
creatic tissue isolated from wild-type mice, using anti-
bodies to survivin, -catenin, Isl1, insulin (Ins),
glucagon (Gluc), and somatostatin (Som). Survivin is
expressed throughout the pancreatic epithelium at
E15.5 (-catenin
, Isl1
 cells), becomes gradually re-
stricted to endocrine (Isl1
) cells in late embryogen-
esis (E19.5) and postnatally (P14), and then is further
restricted to -cells (Ins
) by P21. Magniﬁcation 20.
Bar  20 m. B: Analysis of expression of differentia-
tion markers in pancreatic sections isolated from
Pax6-cre;survivin
lox/lox mice and their littermate con-
trols. Comparisons between mutant (MUT) and litter-
mate controls (WT) indicated similar patterns and
levels of expression at E15.5 and E19.5. Magniﬁcation
20. Bar  20 m. (Please see http://dx.doi.org/10.
2337/db08-0170 for a high-quality digital representa-
tion of this image.)
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weeks of age, Pax6-Cre;survivin
lox/lox mice responded
similarly to littermate control animals when treated with
the same doses (0.75 unit/kg) of exogenous insulin (Fig.
2C), consistent with a primary lack of insulin availability
as the cause of the hyperglycemia due to a loss of survivin.
To further understand this process, we quantiﬁed the
serum insulin of the mice over time. Survivin-deﬁcient
mice had very low to undetectable (below assay thresh-
old) insulin levels from 3 to 13 weeks of life (Fig. 2D;
supplementary Table 1), suggesting either a failure of
insulin production or secretion. Mice with a one-allele loss
of endocrine-survivin (Pax6-Cre;survivin
lox/ mice) had
12-h fasting glucose levels that were comparable with
control animals at 4 and 5 weeks of age (supplementary
Fig. 2A). At 17 weeks of age, however, these heterozygotes
began to develop some signs of glucose intolerance, as
shown by their higher serum glucose levels after dextrose
administration (supplementary Fig. 2B).
Pax6-Cre;survivin
lox/lox mice that remained untreated
and therefore exposed to high serum glucose levels for
several months after birth became relatively resistant to
exogenous insulin, as would be expected (supplementary
Fig. 3A). Many of these older survivin-deﬁcient mice also
developed other metabolic hallmarks of human diabetes,
including metabolic acidosis, hyperkalemia, polyuria, and
ketonuria (supplementary Fig. 3B; supplementary Table
2). In addition, they developed hypertriglyceridemia, hy-
poproteinemia (supplementary Fig. 3C; supplementary Ta-
ble 2), and pathological evidence of fatty livers, most likely
due to the secondary effects of prolonged glucose and lipid
toxicity (supplementary Fig. 3D), ﬁndings reminiscent of
untreated human diabetes. These mice ultimately showed
poor weight gain and signs of dehydration and had short-
ened life spans of 4–7 months.
To determine the cause of the metabolic abnormalities
resulting from the low serum insulin levels, we examined
pancreatic sections from the mice for pathological abnor-
malities over time. The onset of hyperglycemia in mice
lacking survivin within endocrine cells was associated
with a signiﬁcant decrease in the number of insulin-
producing cells after 4 weeks of age as measured by
immunohistochemical staining for insulin (Fig. 3A) and by
islet mass (Fig. 4A), suggesting that there was a lack of
insulin production due to an inappropriate decrease in
-cell number. By contrast, a decrease in the number or
function of - and -cells, as determined by immunohisto-
chemical staining for glucagon and somatostatin (Fig. 3A)
and by measuring serum glucagon levels (Fig. 3B), was not
observed during the early postnatal period. The ﬁndings of
hyperglycemia, insulin deﬁciency, and a lack of insulin-
producing -cells in the face of a relative preservation of
- and -cells suggest that survivin plays an essential role
in the regulation of -cell number early after birth, prefer-
entially affecting these cells over other endocrine sub-
types. Given the known mechanisms of survivin function
in cancer cells, both as an inhibitor of apoptosis and a
regulator of cell division, survivin could have either one or
both functions in pancreatic -cells.
Survivin regulates -cell mass after birth. To establish
the effect of a survivin deletion on the onset and extent of
-cell expansion, we compared the total mass of -cells as
a function of time in Pax6-Cre;survivin
lox/lox versus litter-
mate controls containing both survivin alleles. Although
the -cell masses of the control and mutant animals were
similar at birth, beginning at 2 weeks of age they became
signiﬁcantly smaller in animals lacking survivin within
these cells (0.17 vs. 0.41 mg in littermate controls [n 
5], P 	 0.001; Fig. 4A), reaching a 10-fold reduction at 8
weeks of life (0.12 vs. 1.29 mg [n  4], P 	 0.001; Fig.
4A). Serial examination of pancreatic tissue collected
from control and mutant animals at P0 and at 1, 2, and
3 weeks of age showed that the survivin-deﬁcient cells
had many enlarged, dysmorphic nuclei, characterized by
an increase in nuclear size that was not apparent in the
littermate control cells (mean nuclear size, 37.3 vs. 30.9
m
2 at 2 weeks; 39.7 vs. 31.5 m
2 a t3w e e k s[ n  5],
P 	 0.001; Fig. 4B and C). This phenotype is similar to
that described after the disruption of survivin in cul-
tured cancer cells (35,36) and after homozygous dele-
tion of survivin in murine embryonic cells during early
embryogenesis (18). The morphological defects ob-
served in the -cells lacking survivin are consistent with
WT
MUT
WT
MUT
WT
MUT
Survivin/Ins Gluc/Ins
Nkx2.2/Ins Pax6/Ins
Isl1/Ins MafB/Ins MafA/Ins
Nkx6.1/Ins
Gluc/Ins
P7 E15.5 E19.5
E15.5
E15.5
B
FIG. 1. Continued.
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a role in -cell replication.
Survivin regulates cell division and protects cells
against cell death. To test the hypothesis that survivin
regulates cell division and/or cell death in pancreatic
-cells during a time period shortly after birth, we exam-
ined tissue sections isolated from 2-week-old animals for
the expression of proliferating cell nuclear antigen
(PCNA), a marker of cell cycle proliferation, and for
transferase-mediated dUTP nick-end labeling (TUNEL), a
marker for apoptosis. We observed a 50% decrease in
PCNA staining in the survivin-deﬁcient -cells (Fig. 5A)
but no signiﬁcant change in the number of TUNEL
 cells
(not shown). To increase the sensitivity for the detection
of cell death, we isolated islet cells from the pancreata of
1- to 2-week-old animals and subjected them to functional
caspase 3 activity assays. With this methodology, we did
observe a twofold increase in caspase 3 activity in the
survivin-deﬁcient cells (Fig. 5B), suggesting an effect on a
caspase 3–dependent cell death pathway. To further char-
acterize the cell cycle abnormalities, we performed ﬂow
cytometry analyses on the same isolated islets. This re-
vealed an excess of cells with 
4N modal chromosome
numbers in the survivin-deﬁcient islets (14 vs. 9%; Fig. 5C)
and an accumulation of survivin-deﬁcient islets in late
S/G2 (36 vs. 23%; Fig. 5C), suggesting a delay in cell cycle
progression. To attempt to gain further insight into poten-
tial cell cycle proteins regulated by survivin in -cells, we
performed quantitative PCR on RNA from the isolated
islets for genes involved in cell cycle progression. These
analyses revealed a signiﬁcant (average threefold) in-
crease in expression of the cell cycle inhibitor p21
WAF1
and a twofold decrease in expression in cyclin E in the
survivin-deﬁcient cells (Fig. 5D). No signiﬁcant changes
in the expression levels of Cyclin A, B1, B2, C, D1, F, p27,
Cdk2,o rCdk4 were seen (Fig. 5D). Taken together, our
ﬁndings support the hypothesis that survivin regulates cell
cycle progression in pancreatic -cells. These effects could
be mediated through repression of p21
WAF1, which might
occur as a consequence of survivin-dependent repression
of p53 protein (37,38).
Survivin is functionally speciﬁc for mature pancre-
atic -cells. To establish survivin as a speciﬁc regulator of
-cell mass distinct from other endocrine cell subtypes,
we mated the Pax6-Cre;survivin
lox/lox mice with trans-
genic mice expressing the survivin protein under control
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FIG. 2. Loss of survivin results in insulin-deﬁcient diabetes. A: Mean (SD) random glucose levels in littermate control (survivin
lox/ or
survivin
lox/lox) mice (E, n  8 at each time point) and homozygous survivin-deﬁcient (Pax6-Cre;survivin
lox/lox) mice (f, n  8 at each time point)
at various ages after birth. *Signiﬁcance at P < 0.01. B: Glucose tolerance test (mean  SD) in 6-week-old male littermates. Control (E, n  7)
and homozygous survivin-deﬁcient (f, n  7) mice were fasted for 5 h then injected with dextrose (2 g/kg body wt) intraperitoneally.
*Signiﬁcance at P < 0.05. C: Insulin challenge test in 4-week-old littermates. Four-week-old control (E, n  3) and homozygous survivin-deﬁcient
(f, n  4) mice were injected with 0.75 unit/kg insulin (fed state). No statistically signiﬁcant differences were found at any time point. D: Random
serum insulin levels measured by enzyme-linked immunosorbent assay in age-matched animals at the indicated times. E, insulin levels in
individual control animals (n  16); Œ, levels in individual Pax-6Cre;survivin
lox/lox animals (n  12). See supplementary Table 1 for individual
values.
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lox/lox;RIP-SVV
mice). We then followed the triple transgenic mice from
birth to 8 weeks of age, measuring weekly random serum
glucose concentrations in the Pax-6-Cre;survivin
lox/lox;
RIP-SVV mice and comparing these with random glucose
levels in the RIP-SVV, Pax-6-Cre;survivin
lox/lox, and
survivin
lox/lox mice (Fig. 6A). RIP-driven transgenic
expression of survivin completely rescued the diabetic
phenotype of the Pax6-Cre;survivin
lox/lox mice. It also
restored normal growth (Fig. 6B, 12 weeks) and mass of
the islets (Fig. 6C). This ﬁnding supports a major role for
survivin in maintaining -cell number and function in
normal animals after birth.
DISCUSSION
In this work, we show that survivin, a protein involved in
both replication and apoptosis in cancer cells, plays an
important role in the maintenance of mature pancreatic
-cells after birth. Toward the end of embryonic develop-
ment, survivin expression becomes restricted to -cells
within the endocrine pancreas. Genetic disruption of sur-
vivin in all pancreatic endocrine cell types results in a
selective decrease in the pancreatic -cell mass early after
birth, beginning at 2 weeks of life. Animals lacking survivin
within their pancreatic endocrine cells become hypergly-
cemic and are unable to produce sufﬁcient amounts of
insulin by 4 weeks of life but maintain production of other
endocrine hormones, including glucagon and somatosta-
tin. Interestingly, blood glucose levels in the survivin-
deﬁcient animals were not signiﬁcantly increased at 3
weeks of age, although insulin levels were at least twofold
below normal. A likely explanation for the relative normo-
glycemia at 3 weeks of life is that the animals were
maintained on a low-carbohydrate (maternal milk) diet,
and, thus, the requirements for insulin were low. Once the
animals were weaned to a high-carbohydrate (standard
chow) diet between 3 and 4 weeks, however, the require-
ment for insulin increased, resulting in signiﬁcant hyper-
glycemia in the absence of endogenous insulin. Because of
the hepatic and renal toxicity resulting from massive
hyperglycemia over time, the animals lacking survivin had
shortened life spans. This dramatic phenotype was com-
pletely reversed by exogenously expressing the mouse
survivin protein in mature pancreatic -cells of the sur-
vivin-deﬁcient animals. The molecular mechanism under-
lying the loss of pancreatic -cells in the survivin-
deﬁcient animals, although limited because of the in vivo
nature of this study, is supportive of a defect in both cell
cycle progression and an apoptotic pathway.
Some intriguing questions generated from this work are
1) why does survivin more selectively affect -cells over
other endocrine cell types, and 2) why are there no
observable effects of a loss of survivin during embryogen-
esis? One answer to the cell-selective effect may be that
the expression levels of survivin in the -cells are much
higher than those in the other endocrine subtypes and that
a critical level of survivin is necessary to confer its
function. This hypothesis is consistent with the data here
and also with the effects observed in cancer cells; high
levels of survivin found in malignant human tumor cells
promote tumor cell survival, whereas low survivin levels
inherent to benign tumors confer no survival advantage
(13). Prior evidence for a requirement for -cell–speciﬁc
cell cycle proteins, like survivin, for precise regulation of
proliferation comes from whole mouse knockout models
of other proteins, such as CDK4, that give rise to a
selective -cell phenotype, without affecting additional
endocrine or exocrine cell types (39,40). With regard to the
timing of survivin loss during early embryogenesis and its
effect on postnatal -cells, this could be due to a speciﬁc
necessity for its activation during the rapid proliferative
phase between the end of embryogenesis and the ﬁrst 2
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deﬁnitively, signaling pathways that control the regulation
of survivin protein during embryogenesis and after birth
will need to be explored.
In the mammalian cell cycle, D-type cyclins bind to and
activate the cyclin-dependent kinase protein CDK4 during
G1, and, together, they coordinate the transition from G1
to S phase via phosphorylation of Rb protein and release
of the transcriptional activator E2F1 (43–45). Previously,
we have shown that E2F1 binds to and activates the
survivin promoter in mouse embryonic ﬁbroblasts and is
responsible, in part, for its cell-cycle dependency (46). The
spontaneous development of insulin-deﬁcient diabetes af-
ter deletion of survivin within the endocrine pancreas is
strikingly similar to the phenotype observed after disrup-
tion of Cdk4 in ES cells (39,40). Cdk4-null mice develop
diabetes manifested by hyperglycemia, polyuria, and low
serum insulin levels within the ﬁrst 2 months of life
(39,40). Sections of pancreas tissue from these mice, like
those from the survivin mutant mice, show a decrease in
islet cell mass with a selective decrease in the expression
of insulin and a relative preservation of glucagon, soma-
tostatin, and pancreatic polypeptide. In addition, pancreas
tissue from the Cdk4-null mice show evidence of both a
decrease in -cell proliferation and an increase in apopto-
sis (40), the latter likely induced after activation of a cell
cycle checkpoint in response to a lack of cell cycle
progression (47). Thus, survivin is much like CDK4 in that
it can selectively regulate -cell growth during the postna-
tal period and, when inactivated, causes a slowing of cell
cycle progression and an increase in apoptosis. Given the
similar phenotypes of the Cdk4 and survivin knockout
animals, the E2F1-mediated regulation of survivin tran-
scription, and the activation of E2F1 by the CDK4/CyclinD
complex, survivin ﬁts well within the molecular pathway
of these proteins and likely functions to assist them in
modulating -cell replication after birth. Further work
showing that transgenic expression of survivin can rescue
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way, would conﬁrm this hypothesis.
Although limited by the in vivo nature of this study, by
the technical difﬁculty of isolating sufﬁcient numbers of
islet cells from young (1- to 2-week-old) survivin mutant
mice for protein analysis, and by the extremely low in vitro
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(48), by isolating some islets from the mutant mice, we
were able to use quantitative PCR to identify the cell cycle
regulator p21
WAF1 as consistently induced in islet cells
that lacked survivin. p21 protein, within a family of pro-
teins that also includes p27 and p57, can function to inhibit
(49–51) cyclin-dependent kinases, leading to a decrease in
the rate of cell cycle progression. p21 is expressed in both
human and mouse -cells and is induced in response to
-cell injury (52) and growth factors (53). Functionally,
islet cells lacking p21 grow faster than those with an intact
p21 protein (53). Interestingly, p21 is not induced by
metabolic signals, leading to a suggestion that it speciﬁ-
cally acts to inhibit mitogenic signals in -cells (54). If p21
is a true downstream target of survivin in -cells, then
upregulation of survivin during the developmental period
of -cell growth may result in a decrease in p21 activity,
releasing the cells to proceed through the cell cycle.
Although dispensable for the differentiation of endo-
crine cells during embryonic development, survivin ﬁts
well within the framework of known mediators of cell
cycle progression in mature -cells, including the D-type
cyclins, the cyclin-dependent kinases, the E2F/RB family
of proteins, and the moderators of these molecules, the
cyclin-dependent kinase inhibitors (9,54,55). Our data
strongly support a critical role for survivin in the mainte-
nance of the -cell mass in the early postnatal period.
Understanding -cell mass regulation is critical to under-
standing the pathogenesis of diabetes and to islet cell
transplantation protocols. Our ﬁndings suggest that cur-
rent efforts to regenerate and expand the -cell mass (56)
will need to consider the novel role of survivin during this
process.
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